OS Therapies (NYSE:OSTX) Now Covered by Analysts at Maxim Group

Maxim Group assumed coverage on shares of OS Therapies (NYSE:OSTX) in a report published on Tuesday,Benzinga reports. The brokerage issued a buy rating and a $8.00 price target on the stock.

OSTX has been the topic of a number of other research reports. EF Hutton Acquisition Co. I raised shares of OS Therapies to a “strong-buy” rating in a research note on Tuesday, September 3rd. Brookline Capital Management raised shares of OS Therapies to a “strong-buy” rating in a research note on Thursday, August 22nd.

OS Therapies Trading Down 2.4 %

Shares of OSTX opened at $2.00 on Tuesday. OS Therapies has a 12 month low of $1.58 and a 12 month high of $4.90. The firm has a 50 day simple moving average of $2.81.

Institutional Trading of OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new position in shares of OS Therapies Inc (NYSE:OSTX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.